$40.11
0.972.48%
At Close: -
$40.11
00.00%
After Hours: Aug 23, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Apellis Pharmaceuticals (NASDAQ:APLS) Stock, Earnings Estimates, EPS, And Revenue
Apellis Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Oct 30
EPS Estimate
$-0.260
Quarterly Revenue Estimate
$204.6M
Annual Revenue
(as of Jun 30)
(as of Jun 30)
$628.8M
Analyze the earnings history of Apellis Pharmaceuticals using advanced sorting and filters.
Data brought to you by Benzinga APIs
Apellis Pharmaceuticals (APLS) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Jun 2024 | 2024-08-01 | $-0.28 | $-0.32 | 12.5 % |
| Mar 2024 | 2024-05-07 | $-0.54 | $-0.52 | -3.85 % |
| Dec 2023 | 2024-02-27 | $-0.73 | $-0.69 | -5.80 % |
| Sep 2023 | 2023-11-01 | $-1.17 | $-0.85 | -37.6 % |
Apellis Pharmaceuticals (APLS) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Jun 2024 | 2024-08-01 | $199.69M | $193.78M | 3.05 % |
| Mar 2024 | 2024-05-07 | $172.33M | $163.35M | 5.49 % |
| Dec 2023 | 2024-02-27 | $146.38M | $143.59M | 1.94 % |
| Sep 2023 | 2023-11-01 | $110.40M | $99.74M | 10.7 % |
FAQ
When is Apellis Pharmaceuticals (NASDAQ:APLS) reporting earnings?
Apellis Pharmaceuticals (APLS) is scheduled to report earnings on October 30, 2024. The last reported earnings were for reported on August 1, 2024 for Q2.
What were the latest earnings per share (EPS) for Apellis Pharmaceuticals (NASDAQ:APLS)?
The Actual EPS was $-0.28, which beat the estimate of $-0.32.
What were Apellis Pharmaceuticals’s (NASDAQ:APLS) revenues?
The Actual Revenue was $199.7M, which beat the estimate of $193.8M.
Browse earnings estimates, EPS, and revenue on all stocks.